Generated by Meeveem AI
"Pioneering breakthrough medicines for diabetes, obesity and rare chronic diseases"
Novo Nordisk develops biological medicines for serious chronic diseases including diabetes, obesity, and rare blood and endocrine disorders. Founded in Denmark in 1923, the company translates unmet medical needs into innovative treatments and delivery systems, such as insulin pens, now used in 170 countries. With over 69,000 employees, Novo Nordisk makes therapies accessible to millions worldwide. The company refuses quick fixes, focusing on long-term health solutions. From pioneering longer-acting insulins to breakthrough obesity treatments like semaglutide, Novo Nordisk balances bold science with compassion. A significant portion of profits returns to society through the Novo Nordisk Foundation, funding research and health initiatives.
69000
Team Members
1923
Founded
Pharma
Sector
Hybrid
Work Environment
A world where serious chronic diseases are prevented, managed effectively, and ultimately cured, enabling millions to live healthier, fuller lives without limitation.
At Novo Nordisk, our mission is to drive change to defeat serious chronic diseases by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure the diseases we treat.